Cygnus Technologies
Diamond Exhibitor
Information
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in analytics for host cell proteins (HCP), other process-related impurities, and viral clearance. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release.
Founded in 1997, Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. Cygnus continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology, orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA, as well as MockV™ virus clearance kits. Cygnus’ proprietary technologies, available through its off-the-shelf and custom assays/services, set the gold standard for enabling HCP and other bioprocess impurity antibody and assay development. Cygnus’ quality management program and processes are ISO-9001:2015 certified.
Located in Leland, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.
